Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2020 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Cabozantinib-related posterior reversible encephalopathy syndrome.
Rev Neurol (Paris). 2022 Sep;178(7):746-749. doi: 10.1016/j.neurol.2022.01.010. Epub 2022 Apr 30.
Rev Neurol (Paris). 2022.
PMID: 35504737
No abstract available.
Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology.
Fiteni F, Cuenant A, Favier M, Cousin C, Houede N.
Fiteni F, et al. Among authors: cuenant a.
In Vivo. 2019 Jan-Feb;33(1):17-21. doi: 10.21873/invivo.11433.
In Vivo. 2019.
PMID: 30587597
Free PMC article.
Review.
Item in Clipboard
High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.
Dellal H, Boulahtouf A, Alaterre E, Cuenant A, Grimaldi M, Bourguet W, Gongora C, Balaguer P, Pourquier P.
Dellal H, et al. Among authors: cuenant a.
Cells. 2020 Jun 16;9(6):1469. doi: 10.3390/cells9061469.
Cells. 2020.
PMID: 32560058
Free PMC article.
Item in Clipboard
[Development of a therapeutic education program for prostate cancer patients undergoing new generation hormone therapy].
Cuenant A, Eglin I, Ferreira V, Houédé N.
Cuenant A, et al.
Bull Cancer. 2022 May;109(5):623-629. doi: 10.1016/j.bulcan.2021.11.014. Epub 2022 Jan 10.
Bull Cancer. 2022.
PMID: 35027162
French.
Item in Clipboard
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
Viala M, Vinches M, Alexandre M, Mollevi C, Durigova A, Hayaoui N, Homicsko K, Cuenant A, Gongora C, Gianni L, Tosi D.
Viala M, et al. Among authors: cuenant a.
Br J Cancer. 2018 Mar 6;118(5):679-697. doi: 10.1038/bjc.2017.473. Epub 2018 Feb 13.
Br J Cancer. 2018.
PMID: 29438365
Free PMC article.
Item in Clipboard
Cite
Cite